Healthcare entity
All 1 tracked stories fall under one category: health-it. NAMkind™ Liver is most often covered alongside Antibody Drug Conjugates (ADCs), which appears in 1 of these 1 story. We currently track 1 Healthcare story that mention NAMkind™ Liver, all published on June 30, 2026.
Last mentioned: Jun 30, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: health-it. NAMkind™ Liver is most often covered alongside Antibody Drug Conjugates (ADCs), which appears in 1 of these 1 story. We currently track 1 Healthcare story that mention NAMkind™ Liver, all published on June 30, 2026. Each carries 3 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 5 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering NAMkind™ Liver. Shared-story counts are live from our verified record — not editorial picks.
VivoSim claims its NAMkind platform achieves >90% sensitivity in liver toxicity testing, dramatically reducing false positives that cause expensive drug rejections. This shift aligns with FDA’s drive for human-relevant alternatives to animal testing, promising safer and more efficient drug development.
Source: Globe Newswire · Financialcontent
NAMkind™ Liver is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
